Dallas, TX (February 7, 2024) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced that Dr. Victor Gonzalez will present at the 47th Annual Macula Society Meeting, taking place from Feb 7-10 at the La Quinta Resort & Club in Palm Springs, California. Presentation details are as follows:

Title: MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy Through Week 48 in the Phase 2a STARLIGHT Clinical Trial
Session Title: Inherited Retinal Dystrophy I (Treatment Trials)
Date: February 7, 2024
Time: 6:18 PM-6:25 PM PT
Location: Main Hall
Presenter: Dr. Victor Gonzalez, Valley Retina Institute, McAllen, TX

During his presentation, Dr. Gonzalez will outline the trial design and 48-week data from STARLIGHT (NCT05417126), the first clinical study of optogenetic therapy for severe vision loss from Stargardt disease.  Dr. Gonzalez will cover best-corrected visual acuity (BCVA) improvements of STARLIGHT patients, as measured by ETDRS chart, after a single intravitreal MCO-010 injection. Dr. Gonzalez will also share his thoughts on how the STARLIGHT results can inform the future clinical development of Nanoscope’s Stargardt program as it progresses to Phase 3.

Key results from the STARLIGHT clinical trial

• MCO-010 was well tolerated with no serious adverse events (SAEs) maintained through 48 weeks
• Patients with predominantly macular disease experienced clinically meaningful improvements in BCVA
• Improvements were shown in Visual Field and in patient-reported outcomes (reading and color & contrast)

About Stargardt Disease
Stargardt disease is a rare inherited eye disorder caused by fatty deposits in the macula, leading to center-field loss of vision. It affects approximately 8,000-10,000 patients in the US, often with symptoms beginning in childhood or adolescence. Currently, there are no FDA-approved treatments.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
[email protected]